Annual review of pharmacology and toxicology
-
Annu. Rev. Pharmacol. Toxicol. · Jan 2013
ReviewTyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.
With the manufacture of imatinib, researchers introduced tyrosine kinase inhibitors (TKIs) into the clinical setting in 2000 to treat cancers; approximately fifteen other TKIs soon followed. Imatinib remains the most successful agent, whereas all the others have had modest effects on the cancers that they target. ⋯ One of the most promising approaches is to combine immune therapy with TKI treatment. In this review, the therapeutic potential of TKIs for treatment is discussed.